GlassScriptPhysician profile
Mauricio E Bueno
NPI 1750332029
$2,739.28
in general payments reported to CMS, 2019-2025
23 companies · $97.05 in 2025
The $97.05 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $529 · 2020: $76.09 · 2021: $757 · 2022: $555 · 2023: $324 · 2024: $401 · 2025: $97.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $822.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $513.55 | 2019-2024 | Lifevest |
| Cvrx, INC. | $491.57 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $354.51 | 2021-2024 | |
| Lilly USA, LLC | $278.55 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $237.58 | 2019-2022 | |
| Biotronik INC. | $183.59 | 2019 | |
| Boston Scientific Corporation | $124.01 | 2021 | |
| Mannkind Corporation | $74.92 | 2019-2020 | |
| Novo Nordisk INC | $66.11 | 2023-2024 | Ozempic, Rybelsus |
| Abbott Laboratories | $47.79 | 2021-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $47.32 | 2019-2025 | Gardasil 9, Vaxneuvance, Rotateq |
| Pfizer INC. | $45.95 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $35.26 | 2019-2020 | |
| Abbvie INC. | $34.20 | 2019 | |
| Amgen INC. | $34.13 | 2025 | Krystexxa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $31.60 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.98 | 2022 | |
| Janssen Pharmaceuticals, INC | $22.74 | 2019 | |
| Dexcom, INC. | $22.45 | 2024 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $20.84 | 2023 | |
| Lundbeck LLC | $17.12 | 2024 | Rexulti |
| Glaxosmithkline, LLC. | $15.54 | 2019 | |
| Cranial Technologies, INC | $14.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mauricio Bueno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.